Bio News
Upfront payment of 2.9 trillion won; total transaction valued at 3.2 trillion won Acquisition includes BCMA-targeted T-cell engager sizutamig and other assets

UCB will acquire Candide Therapeutics in a transaction valued at 3.2 trillion won, including an upfront payment of 2.9 trillion won. The acquisition will give UCB four bispecific antibody pipeline programs, including the BCMA-targeted T-cell engager sizutamig. Sizutamig has been studied in more than 100 patients, and clinical trials are currently underway in more than 10 autoimmune indications. The acquisition is expected to close by the second quarter.

Biobook Team
biobookmedia@biobook.co.krInflammation Gene Expression Rises Up to 3.7-Fold in Miniature Pig Intestine
Daewoong Pharmaceutical’s Flodicitinib Achieves More Than 90% Target Occupancy in Phase 1 Trial
Aribio’s AR1001 Meets Primary Endpoint in Phase 3 Alzheimer’s Trial
GC녹십자 Signs MOU With Dongbang FTL to Collaborate on LNP Production
CG Oncology: Cretostimogene Cuts Bladder Cancer Recurrence Risk by 68%; FDA Filing to Expand
CG Oncology: 68% Lower Risk of Bladder Cancer Recurrence; Shares Surge 12%